Tecentriq (atezolizumab) works by removing a “shield” that cancer cells use to hide from your immune system. It belongs to a class of drugs called immune checkpoint inhibitors, and it specifically targets a protein called PD-L1 on the surface of tumor cells. By blocking that protein, Tecentriq allows your T cells to recognize and attack the cancer.
The Immune Shield Cancer Cells Exploit
Your immune system has built-in brakes called checkpoints. These exist for a good reason: they prevent your T cells from attacking your own healthy tissue. One key checkpoint involves two proteins, PD-1 and PD-L1, that fit together like a lock and key. When PD-L1 on a cell’s surface connects with PD-1 on a T cell, it sends a “stand down” signal. The T cell backs off.
Many cancers hijack this system. Tumor cells produce large amounts of PD-L1 on their surface, essentially disguising themselves as normal tissue. When a T cell approaches and its PD-1 receptor locks onto the tumor’s PD-L1, the T cell receives that same “stand down” signal and stops its attack. The tumor grows unchecked while your immune system is tricked into tolerating it.
How Tecentriq Removes That Shield
Tecentriq is an engineered antibody designed to bind directly to PD-L1 on tumor cells. Once it latches on, it physically blocks PD-L1 from connecting with PD-1 on T cells. Without that “stand down” signal, your T cells remain active. They can now recognize the tumor as a threat and mount an attack against it.
This is different from some other checkpoint inhibitors that target PD-1 on the T cell side. Tecentriq works from the tumor side, blocking the ligand (PD-L1) rather than the receptor. The end result is similar: the immune brake is released, and your T cells can do their job.
Cancers Tecentriq Is Approved to Treat
Tecentriq is FDA-approved for several cancer types, sometimes alone and sometimes combined with other treatments.
Non-small cell lung cancer (NSCLC) is the broadest category. Tecentriq can be used as a single drug after surgery and chemotherapy for stage II to IIIA NSCLC when tumors express PD-L1 on at least 1% of cells. For metastatic NSCLC with high PD-L1 expression (50% or more of tumor cells), it can be a first-line standalone treatment. It’s also approved in combination with chemotherapy drugs for metastatic non-squamous NSCLC, and as a later-line option for patients whose cancer has progressed after platinum-based chemotherapy.
Small cell lung cancer in its extensive stage is treated with Tecentriq combined with carboplatin and etoposide chemotherapy. In the pivotal IMpower133 trial, this combination extended median overall survival to 12.3 months compared to 10.3 months with chemotherapy alone.
Liver cancer (hepatocellular carcinoma) that can’t be surgically removed is treated with Tecentriq plus bevacizumab as a first-line option. Updated trial data showed a median overall survival of 19.2 months with this combination, and about 30% of patients saw their tumors shrink meaningfully.
Tecentriq is also approved for BRAF-mutant melanoma in combination with two targeted therapy drugs, and for alveolar soft part sarcoma, a rare soft tissue cancer, in adults and children aged 2 and older.
PD-L1 Testing Before Treatment
Not every patient needs a PD-L1 test before starting Tecentriq. It depends on the cancer type and the treatment plan. For certain NSCLC uses, particularly when Tecentriq is given alone, your tumor must show a minimum level of PD-L1 expression. A pathologist determines this by staining a tissue sample and measuring the percentage of cells that display PD-L1.
When Tecentriq is combined with chemotherapy, PD-L1 testing is sometimes not required because the combination has shown benefit regardless of expression levels. Your oncologist will determine whether testing is necessary based on your specific situation and the planned treatment approach.
What Treatment Looks Like
Tecentriq is given as an intravenous infusion, typically at a dose of 1,200 mg every three weeks. The first infusion takes about 60 minutes. If you tolerate that well, subsequent sessions can be shortened to around 30 minutes. Treatment continues on this three-week cycle until the cancer progresses or side effects become unmanageable.
Because Tecentriq is a large protein (an antibody), your body breaks it down the same way it processes other proteins, recycling it into amino acids. It has a long half-life of about 27 days, which is why dosing every three weeks maintains effective levels in your bloodstream.
Side Effects and Immune Reactions
Since Tecentriq works by releasing the brakes on your immune system, the most notable side effects happen when that newly activated immune response overshoots and attacks healthy tissue. These are called immune-related adverse events, and in a large analysis of over 1,500 NSCLC patients treated with Tecentriq, about 48% experienced at least one.
Most of these reactions are mild to moderate. The most common is skin rash, affecting about 28% of patients, though only 2% develop a severe form. Liver inflammation (hepatitis) occurs in roughly 15% of patients, with 5% experiencing serious cases. Thyroid problems are also relatively common: about 12% develop an underactive thyroid and 4% an overactive one. These thyroid changes are rarely severe and are often manageable with hormone replacement.
Less common but more serious immune reactions include lung inflammation (pneumonitis) in about 6% of patients, with 2% developing severe cases, and colitis (inflammation of the colon) in about 2%. Serious immune reactions affecting the heart, kidneys, or pituitary gland occur in fewer than 1% of patients. Overall, 11% of all Tecentriq-treated patients in this analysis experienced a grade 3 or higher immune reaction, meaning one severe enough to require active medical intervention.
Your treatment team will monitor blood work regularly to catch these reactions early. Most immune-related side effects are reversible when identified quickly, and they’re typically treated by temporarily pausing Tecentriq and using medications that calm the immune response.